Allostery Investments LP acquired a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 25,000 shares of the company's stock, valued at approximately $545,000. Dianthus Therapeutics makes up approximately 0.6% of Allostery Investments LP's investment portfolio, making the stock its 26th biggest holding. Allostery Investments LP owned approximately 0.08% of Dianthus Therapeutics at the end of the most recent reporting period.
Several other hedge funds also recently modified their holdings of DNTH. MetLife Investment Management LLC increased its position in Dianthus Therapeutics by 3.1% in the 4th quarter. MetLife Investment Management LLC now owns 14,372 shares of the company's stock valued at $313,000 after acquiring an additional 433 shares during the period. Invesco Ltd. increased its stake in shares of Dianthus Therapeutics by 7.4% in the fourth quarter. Invesco Ltd. now owns 11,521 shares of the company's stock valued at $251,000 after buying an additional 790 shares during the period. SG Americas Securities LLC raised its position in shares of Dianthus Therapeutics by 9.2% during the fourth quarter. SG Americas Securities LLC now owns 9,653 shares of the company's stock worth $210,000 after acquiring an additional 814 shares during the last quarter. Barclays PLC lifted its stake in shares of Dianthus Therapeutics by 2.6% in the fourth quarter. Barclays PLC now owns 42,766 shares of the company's stock worth $933,000 after acquiring an additional 1,082 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Dianthus Therapeutics by 0.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 167,021 shares of the company's stock valued at $3,641,000 after acquiring an additional 1,092 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company's stock.
Dianthus Therapeutics Stock Performance
Shares of Dianthus Therapeutics stock traded down $0.16 on Wednesday, hitting $19.79. The company had a trading volume of 70,370 shares, compared to its average volume of 264,216. Dianthus Therapeutics, Inc. has a 1 year low of $13.37 and a 1 year high of $32.27. The stock has a 50 day moving average of $19.85 and a 200-day moving average of $22.57. The stock has a market capitalization of $635.81 million, a price-to-earnings ratio of -7.94 and a beta of 1.48.
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The firm had revenue of $1.33 million during the quarter, compared to analyst estimates of $1.40 million. Equities analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of brokerages have commented on DNTH. Guggenheim reaffirmed a "buy" rating and set a $84.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Wedbush reaffirmed an "outperform" rating and set a $36.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Finally, HC Wainwright reissued a "buy" rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $54.33.
Read Our Latest Report on DNTH
Dianthus Therapeutics Company Profile
(
Free Report)
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Further Reading
Before you consider Dianthus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dianthus Therapeutics wasn't on the list.
While Dianthus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
